Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 83

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 3
Chunk 83
---

our products and their environmental impact on sustainability, or increased customer and consumer concerns or perceptions (whether accurate
or inaccurate) regarding the effects of substances present in certain of our products. Complying with these demands or requirements could
cause us to incur additional manufacturing, operating or product development costs.

If we do not adapt to or comply with new regulations,
including the SEC’s published proposed rules that would require companies to provide significantly expanded climate-related disclosures
in their periodic reporting, which may require us to incur significant additional costs to comply and impose increased oversight obligations
on our management and board of directors, or fail to meet evolving investor, industry or stakeholder expectations and concerns regarding
ESG issues, investors may reconsider their capital investment in our Company, we may become subject to penalties, and customers and consumers
may choose to stop purchasing our products, if approved for commercialization, which could have a material adverse effect on our reputation,
business or financial condition.

Our employees and independent contractors may engage in misconduct
or other improper activities, including noncompliance with regulatory standards and requirements.

We are exposed to the risk of fraud or other misconduct
by our employees and independent contractors. Misconduct by these parties could include intentional failures to comply with FDA regulations,
provide accurate information to the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare
fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular,
sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent
fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range
of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee
and independent contractor misconduct could also involve the improper use of information obtained in the course of clinical trials, including
individually identifiable information, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation
of product candidates, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify
and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be
effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or
lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that